ATE321859T1 - B2microglobulin fusionsproteine und varianten mit hoher affinität - Google Patents

B2microglobulin fusionsproteine und varianten mit hoher affinität

Info

Publication number: ATE321859T1
Authority: AT; Austria
Prior art keywords: fusion proteins; microglobulin; beta; mhc; variants
Prior art date: 1998-06-10

Application number

AT99928376T

Other languages

English (en)

Inventor

Randall K Ribaudo

Michael Shields

Original Assignee

Us Gov Health & Human Serv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-06-10

Filing date

1999-06-03

Publication date

2006-04-15

1999-06-03 Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv

2006-04-15 Application granted granted Critical

2006-04-15 Publication of ATE321859T1 publication Critical patent/ATE321859T1/de

Links

102000037865 fusion proteins Human genes 0.000 title abstract 5
108020001507 fusion proteins Proteins 0.000 title abstract 5
102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 title 1
101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 title 1
230000005867 T cell response Effects 0.000 abstract 2
102000015736 beta 2-Microglobulin Human genes 0.000 abstract 2
108010081355 beta 2-Microglobulin Proteins 0.000 abstract 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 abstract 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
150000001413 amino acids Chemical group 0.000 abstract 1
239000000427 antigen Substances 0.000 abstract 1
102000036639 antigens Human genes 0.000 abstract 1
108091007433 antigens Proteins 0.000 abstract 1
210000004027 cell Anatomy 0.000 abstract 1
102000047279 human B2M Human genes 0.000 abstract 1
210000004962 mammalian cell Anatomy 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1
230000007704 transition Effects 0.000 abstract 1
239000012646 vaccine adjuvant Substances 0.000 abstract 1
229940124931 vaccine adjuvant Drugs 0.000 abstract 1
239000004474 valine Substances 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Molecular Biology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT99928376T 1998-06-10 1999-06-03 B2microglobulin fusionsproteine und varianten mit hoher affinität ATE321859T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US8881398P	1998-06-10	1998-06-10

Publications (1)

Publication Number	Publication Date
ATE321859T1 true ATE321859T1 (de)	2006-04-15

Family

ID=22213644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99928376T ATE321859T1 (de)	1998-06-10	1999-06-03	B2microglobulin fusionsproteine und varianten mit hoher affinität

Country Status (5)

Country	Link
EP (1)	EP1086224B1 (de)
AT (1)	ATE321859T1 (de)
AU (1)	AU4545799A (de)
DE (1)	DE69930630T2 (de)
WO (1)	WO1999064597A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458354B1 (en)	1996-03-28	2002-10-01	The Johns Hopkins University	Molecular complexes which modify immune responses
EP0889964A1 (de)	1996-03-28	1999-01-13	The Johns Hopkins University	Lösliche divalente und multivalente heterodimäre proteinanalogen
US6268411B1 (en)	1997-09-11	2001-07-31	The Johns Hopkins University	Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP1234031B2 (de)	1999-11-30	2021-11-24	Mayo Foundation For Medical Education And Research	B7-h1, ein neuartiges immunregulierendes molekül
GB9929993D0 (en) *	1999-12-17	2000-02-09	Avidex Ltd	Substances
US7030219B2 (en)	2000-04-28	2006-04-18	Johns Hopkins University	B7-DC, Dendritic cell co-stimulatory molecules
GB0026812D0 (en) *	2000-11-02	2000-12-20	Isis Innovation	Cancer therapy
WO2003029475A1 (fr) *	2001-09-28	2003-04-10	Dnavec Research Inc.	Vecteur viral infectant une cellule de mammifere, codant pour la $g(b)2m liee a un epitope
US9809654B2 (en)	2002-09-27	2017-11-07	Vaccinex, Inc.	Targeted CD1d molecules
US7432351B1 (en)	2002-10-04	2008-10-07	Mayo Foundation For Medical Education And Research	B7-H1 variants
WO2004087058A2 (en) *	2003-03-28	2004-10-14	Vaccinex, Inc.	Targeted mhc class i alpha3 vaccine delivery systems
WO2005099361A2 (en) *	2003-07-10	2005-10-27	Vaccinex, Inc.	MHC CLASS I - PEPTIDE-ANTIBODY CONJUGATES WITH MODIFIED β2-MICROGLOBULIN
DK3428191T3 (da)	2004-10-06	2025-01-02	Mayo Found Medical Education & Res	B7-h1 og pd-1 til behandling af renalcellekarcinom
JP5357782B2 (ja)	2007-02-21	2013-12-04	バクシネックスインコーポレーティッド	抗原負荷ＣＤ１ｄ分子によるＮＫＴ細胞活性の調節
JP2012500652A (ja) *	2008-08-25	2012-01-12	アンプリミューン、インコーポレーテッド	標的化共刺激ポリペプチドおよび癌を処置するための使用方法
AU2010203451B2 (en)	2009-01-08	2016-06-30	Albert Einstein College Of Medicine, Inc.	Bacterial vaccines with cell wall-associated ceramide-like glycolipids and uses thereof
PE20141212A1 (es) *	2011-06-22	2014-09-19	Hoffmann La Roche	Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase 1
CN102391377B (zh) *	2011-11-01	2013-11-06	孙嘉琳	一种可诱导和激活癌靶向t细胞的融合蛋白及制备方法及用途
WO2014096015A1 (en)	2012-12-21	2014-06-26	F. Hoffmann-La Roche Ag	Disulfide-linked multivalent mhc class i comprising multi-function proteins
KR102167438B1 (ko)	2013-02-08	2020-10-19	백시넥스 인코포레이티드	변형된 당지질들 및 이들을 제조하고 사용하는 방법들
US9371352B2 (en)	2013-02-08	2016-06-21	Vaccinex, Inc.	Modified glycolipids and methods of making and using the same
US9302005B2 (en)	2013-03-14	2016-04-05	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
EP3470081A1 (de)	2013-10-01	2019-04-17	Mayo Foundation for Medical Education and Research	Verfahren zur behandlung von krebs bei patienten mit erhöhten bim-werten
US10302653B2 (en)	2014-05-22	2019-05-28	Mayo Foundation For Medical Education And Research	Distinguishing antagonistic and agonistic anti B7-H1 antibodies
EP3171896A4 (de)	2014-07-23	2018-03-21	Mayo Foundation for Medical Education and Research	Abzielung auf dna-pkcs und b7-h1 zur behandlung von krebs
US10875923B2 (en)	2015-10-30	2020-12-29	Mayo Foundation For Medical Education And Research	Antibodies to B7-H1
WO2020092839A1 (en)	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
CA3116412A1 (en)	2018-10-31	2020-05-07	Humanigen, Inc.	Materials and methods for treating cancer
EP3873540A4 (de)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	Verfahren und materialien zur behandlung von krebs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5574205A (en) *	1989-07-25	1996-11-12	Cell Genesys	Homologous recombination for universal donor cells and chimeric mammalian hosts
US5733550A (en) *	1990-05-10	1998-03-31	Dana-Farber Cancer Institute, Inc.	Method for enhancing the association of exogenous peptides with class I MHC molecules on the surface of antigen presenting cells with β-microglobulin
US5314813A (en) *	1992-02-19	1994-05-24	Scripps Research Institute	Drosophila cell lines expressing genes encoding MHC class I antigens and B2-microglobulin and capable of assembling empty complexes and methods of making said cell lines
GB9307371D0 (en) *	1993-04-08	1993-06-02	Walls Alan J	Fusion proteins

1999
- 1999-06-03 AU AU45457/99A patent/AU4545799A/en not_active Abandoned
- 1999-06-03 WO PCT/US1999/012309 patent/WO1999064597A1/en not_active Ceased
- 1999-06-03 EP EP99928376A patent/EP1086224B1/de not_active Expired - Lifetime
- 1999-06-03 AT AT99928376T patent/ATE321859T1/de not_active IP Right Cessation
- 1999-06-03 DE DE69930630T patent/DE69930630T2/de not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AU4545799A (en)	1999-12-30
DE69930630T2 (de)	2007-01-18
EP1086224A1 (de)	2001-03-28
WO1999064597A1 (en)	1999-12-16
EP1086224B1 (de)	2006-03-29
DE69930630D1 (de)	2006-05-18

Legal Events

Date	Code	Title	Description
2006-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69930630D1 (de)	2006-05-18	B2microglobulin fusionsproteine und varianten mit hoher affinität
EP0675136A3 (de)	1996-03-13	Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung.
DE69636891D1 (de)	2007-03-22	Immunstimulierende zusammensetzung und verfahren
DE68924162D1 (de)	1995-10-12	Stressproteine und verwendungen dafür.
ATE229978T1 (de)	2003-01-15	Helicobacter proteine und impstoffe
DK0733067T3 (da)	1999-11-01	N-terminalt kemisk modificerede proteinpræparater og fremgangsmåder
CA2103887A1 (en)	1993-06-14	Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
DE68918867D1 (de)	1994-11-17	Mutanten des hiv-1 Hüllproteins mit fehlenden hypervariabelen domänen.
GB9224584D0 (en)	1993-01-13	Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases
ATE272070T1 (de)	2004-08-15	Lösliche monovalente und multivalente mhc klasse ii fusionsproteine und deren verwendungen
AU573523B2 (en)	1988-06-16	Functional human urokinase proteins
DK0759067T3 (da)	2001-10-22	Transformerende vækstfaktor alfa-H1
DE69922958D1 (de)	2005-02-03	Hcv hüllproteine partikel : verwendung für therapeutische impfung
NZ512083A (en)	2003-02-28	Methods of increasing lean tissue mass using OB protein compositions
DE69535719D1 (de)	2008-04-10	Fas-antigenbindender ligand
DK0754229T3 (da)	1999-07-19	Afamin: et humant serum albumin-lignende protein
DE69434413D1 (de)	2005-08-04	Fusionsproteine zwischen antigene aminosäuresequenzen und beta - 2- mikroglobulin
BR9509172A (pt)	1997-11-25	Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
DE68915046D1 (de)	1994-06-09	Haemophilus influenzae Typ B Polysaccharid-Aussermembranprotein-Konjugat als Impfstoff.
DK1431391T3 (da)	2005-12-19	RANTES-mutanter og terapeutiske anvendelser heraf
EP0369816A3 (de)	1990-09-12	Gegen menschliches polymorphes epitheliales Muzin spezifische monoklonale Antikörper
ATE265234T1 (de)	2004-05-15	Pharmazeutische zusammensetzung von hydrophob modifizierten hedgehog-proteinen und deren verwendung
ATE130872T1 (de)	1995-12-15	Ancrod ähnliche proteine, ihre herstellung und verwendung.
ZA896942B (en)	1990-08-29	Allelic variants of plasmodium falciparum merozoite surface antigen
GB2244273A (en)	1991-11-27	Allelic variants of plasmodium falciparum merozoite surface antigen.